SEI Investments’s Krystal Biotech KRYS Stock Holding History

SEI Investments’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.1M	Buy	54,040 +7,470	+16%	+$2.23M	0.02%	805
2026 Q1	$12M	Buy	46,570 +14,260	+44%	+$3.79M	0.01%	1032
2025 Q4	$7.97M	Buy	32,310 +8,917	+38%	+$1.88M	0.01%	1164
2025 Q3	$4.13M	Buy	23,393 +4,093	+21%	+$613K	﹤0.01%	1382
2025 Q2	$2.65M	Buy	19,300 +609	+3%	+$89.5K	﹤0.01%	1541
2025 Q1	$3.37M	Sell	18,691 -2,473	-12%	-$416K	﹤0.01%	1432
2024 Q4	$3.32M	Sell	21,164 -13,085	-38%	-$2.32M	﹤0.01%	1471
2024 Q3	$6.23M	Sell	34,249 -5,866	-15%	-$1.13M	0.01%	1193
2024 Q2	$7.37M	Buy	40,115 +6,363	+19%	+$1.07M	0.01%	1051
2024 Q1	$6.01M	Buy	33,752 +18,968	+128%	+$2.63M	0.01%	1120
2023 Q4	$1.83M	Sell	14,784 -20,117	-58%	-$2.23M	﹤0.01%	1645
2023 Q3	$4.05M	Buy	34,901 +21,670	+164%	+$2.64M	0.01%	1271
2023 Q2	$1.55M	Buy	13,231 +279	+2%	+$28.5K	﹤0.01%	1727
2023 Q1	$1.04M	Sell	12,952 -3,558	-22%	-$280K	﹤0.01%	1859
2022 Q4	$1.31M	Sell	16,510 -380	-2%	-$28.2K	﹤0.01%	1664
2022 Q3	$1.18M	Sell	16,890 -200	-1%	-$14.4K	﹤0.01%	1740
2022 Q2	$1.12M	Sell	17,090 -2,323	-12%	-$145K	﹤0.01%	1783
2022 Q1	$1.29M	Buy	19,413 +2,998	+18%	+$187K	﹤0.01%	1722
2021 Q4	$1.15M	Buy	16,415 +9,437	+135%	+$549K	﹤0.01%	1792
2021 Q3	$364K	Sell	6,978 -133	-2%	-$7.87K	﹤0.01%	2232
2021 Q2	$484K	Sell	7,111 -139	-2%	-$9.7K	﹤0.01%	2108
2021 Q1	$559K	Sell	7,250 -256	-3%	-$18.6K	﹤0.01%	1975
2020 Q4	$450K	Hold	7,506	–	–	﹤0.01%	2035
2020 Q3	$323K	Hold	7,506	–	–	﹤0.01%	2071
2020 Q2	$311K	Sell	7,506 -2,084	-22%	-$100K	﹤0.01%	2071
2020 Q1	$415K	Buy	9,590 +938	+11%	+$49.1K	﹤0.01%	1799
2019 Q4	$479K	Sell	8,652 -2,148	-20%	-$105K	﹤0.01%	1948
2019 Q3	$375K	Sell	10,800 -1,301	-11%	-$58.2K	﹤0.01%	2021
2019 Q2	$487K	Buy	+12,101	New	+$396K	﹤0.01%	1892

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

SEI Investments's KRYS Position: Q2 2026 in Review

SEI Investments increased its Krystal Biotech (KRYS) stake by 16% in Q2 2026, buying an estimated $2.23M and bringing the position to 54,040 shares worth $20.1M. The position accounts for 0.02% of the portfolio, ranked #805.

SEI Investments first reported a position in KRYS in Q2 2019 and has held it in 29 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

SEI Investments held 54,040 shares of Krystal Biotech worth $20.1M as of Q2 2026.
SEI Investments bought 7,470 Krystal Biotech shares in Q2 2026, an estimated $2.23M.
Krystal Biotech made up 0.02% of SEI Investments's portfolio in Q2 2026, its #805 holding.
SEI Investments first reported a position in Krystal Biotech in Q2 2019 and has held it in 29 quarters since.
423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.